Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4652 USD | -6.04% | -9.11% | -28.43% |
Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
Mar. 25 | Top Premarket Gainers | MT |
Business Summary
Number of employees: 2
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 19-09-09 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 20-07-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-18 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-18 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 20-06-18 |
William McVicar
CHM | Chairman | 66 | 19-07-18 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Tess Burleson
BRD | Director/Board Member | 57 | 19-07-18 |
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,776,433 | 4,486,213 ( 93.92 %) | 0 | 93.92 % |
Company contact information
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.43% | 2.14M | |
+2.21% | 42.75B | |
+47.70% | 41.61B | |
+11.42% | 41.34B | |
-12.36% | 26.59B | |
+8.30% | 25.49B | |
-23.01% | 18.12B | |
+30.86% | 12.24B | |
-1.44% | 11.76B | |
+8.46% | 11B |
- Stock Market
- Equities
- SLRX Stock
- Company Salarius Pharmaceuticals, Inc.